Welcome to GTx, a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions.
Our recognized scientific expertise is in the discovery and development of novel, selective small molecules that target established hormone pathways. Click to learn more about our products in development.
GTx is transforming from a company focused on the discovery and development of drug candidates into one that will also commercialize our products. Click to learn more about the GTx management team.
GTx Provides Corporate Update and Reports First Quarter 2012 Financial Results 
GTx Announces Removal of Full Clinical Hold By FDA for Capesaris(R) In Advanced Prostate Cancer
GTx, Inc. To Host First Quarter 2012 Financial Results Conference Call and Webcast